Disease Burden and Pharmacological Treatment Patterns in Children and Adults With Phenylketonuria: A Real‐World Matched Cohort Study
Journal of Inherited Metabolic Disease · 2026
DOI: 10.1002/jimd.70194 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Journal of Inherited Metabolic Disease, 2026. Verfasst von Nicola Longo und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Human Genetics, Division of Clinical Genetics, University of California, Los Angeles, California, USA. Hauptthemen laut MEDLINE: Phenylketonurias, Cost of Illness. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Moderna.
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
Phenylketonuria (PKU) is caused by defective catabolism of phenylalanine (Phe), resulting in Phe accumulation and subsequent neurocognitive impairment. This retrospective study used a large United States claims database linked to laboratory records (6/2018–05/2023) to compare comorbidities, healthcare resource utilization, and healthcare costs between individuals with PKU and matched controls, stratified by age and Phe level, as well as describe pharmacological treatment patterns among individuals with PKU. The study included 5729 and 2648 matched pairs aged ≥ 12 and < 12 years, respectively (mean age: 31 and 3 years; 60% and 47% female). Individuals aged ≥ 12 years with PKU had significantly higher prevalence of neuropsychiatric and cognitive comorbidities than controls, including intellectual or developmental disabilities (prevalence difference: 5.2%), fatigue and malaise (4.9%), and anxiety (4.2%; all p < 0.05), along with other comorbidities across multiple organ systems. Individuals aged ≥ 12 years with PKU also accessed the healthcare system more than controls (39% more hospitalizations, 18% more emergency room visits, and 25% more outpatient visits) and incurred higher medical and pharmacy costs ($2869 and $9075, respectively; p < 0.05). Individuals aged < 12 years similarly had higher burden than controls, but only for certain outcomes and at smaller magnitudes. Individuals with Phe ≥ 600 μmol/L showed a greater incremental burden for certain comorbidities, such as intellectual or developmental disabilities, compared to individuals with Phe < 600 μmol/L. These findings demonstrate the substantial burden of PKU across age and Phe level strata, notably in those aged ≥ 12 years, highlighting the need for improved treatments.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Human Genetics, Division of Clinical Genetics, University of California, Los Angeles, California, USA.
- Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.
- Moderna, Inc., Cambridge, Massachusetts, USA.
- HealthEcon Consulting, Inc., Ancaster, Ontario, Canada.
- Analysis Group, Boston, Massachusetts, USA.
- Moderna, Inc., Princeton, New Jersey, USA.
ORCID-Profile: Nicola Longo, Barbara K Burton, Shailja Vaghela, Fan Mu, Aolin Wang, Jess Smith, Emily Reichert, Ryan B Simpson, Vanja Sikirica, Sue Perera
Förderung
- Moderna
Zitieren
APA
Longo, N., Burton, B. K., Vaghela, S., Mu, F., Wang, A., Smith, J., Reichert, E., Simpson, R. B., Sikirica, V., & Perera, S. (2026). Disease Burden and Pharmacological Treatment Patterns in Children and Adults With Phenylketonuria: A Real‐World Matched Cohort Study. Journal of Inherited Metabolic Disease. https://doi.org/10.1002/jimd.70194
Vancouver
Longo N, Burton BK, Vaghela S, Mu F, Wang A, Smith J, et al. Disease Burden and Pharmacological Treatment Patterns in Children and Adults With Phenylketonuria: A Real‐World Matched Cohort Study. Journal of Inherited Metabolic Disease. 2026. doi:10.1002/jimd.70194
BibTeX
@article{Longo2026,
author = {Longo, Nicola and Burton, Barbara K and Vaghela, Shailja and Mu, Fan and Wang, Aolin and Smith, Jess and Reichert, Emily and Simpson, Ryan B and Sikirica, Vanja and Perera, Sue},
title = {Disease Burden and Pharmacological Treatment Patterns in Children and Adults With Phenylketonuria: A Real‐World Matched Cohort Study},
journal = {Journal of Inherited Metabolic Disease},
year = {2026},
doi = {10.1002/jimd.70194}
}
EUVIMED